180 related articles for article (PubMed ID: 32183719)
1. Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma.
Xiong Y; Neskey DM; Horton JD; Paulos CM; Knochelmann HM; Armeson KE; Young MRI
BMC Cancer; 2020 Mar; 20(1):229. PubMed ID: 32183719
[TBL] [Abstract][Full Text] [Related]
2. Reduction of T Lymphoma Cells and Immunological Invigoration in a Patient Concurrently Affected by Melanoma and Sezary Syndrome Treated With Nivolumab.
Narducci MG; Tosi A; Frezzolini A; Scala E; Passarelli F; Bonmassar L; Monopoli A; Accetturi MP; Cantonetti M; Antonini Cappellini GC; De Galitiis F; Rosato A; Picozza M; Russo G; D'Atri S
Front Immunol; 2020; 11():579894. PubMed ID: 33072126
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.
Knochelmann HM; Horton JD; Liu S; Armeson K; Kaczmar JM; Wyatt MM; Richardson MS; Lomeli SH; Xiong Y; Graboyes EM; Lentsch EJ; Hornig JD; Skoner J; Stalcup S; Spampinato MV; Garrett-Mayer E; O'Quinn EC; Timmers CD; Romeo MJ; Wrangle JM; Young MRI; Rubinstein MP; Day TA; Lo RS; Paulos CM; Neskey DM
Cell Rep Med; 2021 Oct; 2(10):100426. PubMed ID: 34755137
[TBL] [Abstract][Full Text] [Related]
4. Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature.
Sabbatino F; Marra A; Liguori L; Scognamiglio G; Fusciello C; Botti G; Ferrone S; Pepe S
J Immunother Cancer; 2018 Nov; 6(1):126. PubMed ID: 30458852
[TBL] [Abstract][Full Text] [Related]
5. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
6. The role of tumor cells in the modification of T lymphocytes activity--the expression of the early CD69+, CD71+ and the late CD25+, CD26+, HLA/DR+ activation markers on T CD4+ and CD8+ cells in squamous cell laryngeal carcinoma. Part I.
Starska K; Głowacka E; Kulig A; Lewy-Trenda I; Bryś M; Lewkowicz P
Folia Histochem Cytobiol; 2011; 49(4):579-92. PubMed ID: 22252752
[TBL] [Abstract][Full Text] [Related]
7. Immunophenotyping of patients with oral squamous cell carcinoma in peripheral blood and associated tumor tissue.
Grimm M; Feyen O; Hofmann H; Teriete P; Biegner T; Munz A; Reinert S
Tumour Biol; 2016 Mar; 37(3):3807-16. PubMed ID: 26474587
[TBL] [Abstract][Full Text] [Related]
8. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.
Liu S; Knochelmann HM; Lomeli SH; Hong A; Richardson M; Yang Z; Lim RJ; Wang Y; Dumitras C; Krysan K; Timmers C; Romeo MJ; Krieg C; O'Quinn EC; Horton JD; Dubinett SM; Paulos CM; Neskey DM; Lo RS
Cell Rep Med; 2021 Oct; 2(10):100411. PubMed ID: 34755131
[TBL] [Abstract][Full Text] [Related]
9. GITR ligation enhances functionality of tumor-infiltrating T cells in hepatocellular carcinoma.
van Beek AA; Zhou G; Doukas M; Boor PPC; Noordam L; Mancham S; Campos Carrascosa L; van der Heide-Mulder M; Polak WG; Ijzermans JNM; Pan Q; Heirman C; Mahne A; Bucktrout SL; Bruno MJ; Sprengers D; Kwekkeboom J
Int J Cancer; 2019 Aug; 145(4):1111-1124. PubMed ID: 30719701
[TBL] [Abstract][Full Text] [Related]
10. The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC.
Mazzaschi G; Facchinetti F; Missale G; Canetti D; Madeddu D; Zecca A; Veneziani M; Gelsomino F; Goldoni M; Buti S; Bordi P; Aversa F; Ardizzoni A; Quaini F; Tiseo M
Lung Cancer; 2019 Jan; 127():153-163. PubMed ID: 30642544
[TBL] [Abstract][Full Text] [Related]
11. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
12. High Stromal TGFBI in Lung Cancer and Intratumoral CD8-Positive T Cells were Associated with Poor Prognosis and Therapeutic Resistance to Immune Checkpoint Inhibitors.
Nakazawa N; Yokobori T; Kaira K; Turtoi A; Baatar S; Gombodorj N; Handa T; Tsukagoshi M; Ubukata Y; Kimura A; Kogure N; Ogata K; Maeno T; Sohda M; Yajima T; Shimizu K; Mogi A; Kuwano H; Saeki H; Shirabe K
Ann Surg Oncol; 2020 Mar; 27(3):933-942. PubMed ID: 31571056
[TBL] [Abstract][Full Text] [Related]
13. Tim-3-expressing macrophages are functionally suppressed and expanded in oral squamous cell carcinoma due to virus-induced Gal-9 expression.
Dong J; Cheng L; Zhao M; Pan X; Feng Z; Wang D
Tumour Biol; 2017 May; 39(5):1010428317701651. PubMed ID: 28466780
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of PD-1 blockade in cervical cancer is related to a CD8
Heeren AM; Rotman J; Stam AGM; Pocorni N; Gassama AA; Samuels S; Bleeker MCG; Mom CH; Zijlmans HJMAA; Kenter GG; Jordanova ES; de Gruijl TD
J Immunother Cancer; 2019 Feb; 7(1):43. PubMed ID: 30755279
[TBL] [Abstract][Full Text] [Related]
15. Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer.
Ottonello S; Genova C; Cossu I; Fontana V; Rijavec E; Rossi G; Biello F; Dal Bello MG; Tagliamento M; Alama A; Coco S; Boccardo S; Vanni I; Ferlazzo G; Moretta L; Grossi F; Mingari MC; Carrega P; Pietra G
Front Immunol; 2020; 11():125. PubMed ID: 32117275
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immune responses to anti-PD-1 mono and combination immunotherapy in hematopoietic humanized mice implanted with tumor xenografts.
Capasso A; Lang J; Pitts TM; Jordan KR; Lieu CH; Davis SL; Diamond JR; Kopetz S; Barbee J; Peterson J; Freed BM; Yacob BW; Bagby SM; Messersmith WA; Slansky JE; Pelanda R; Eckhardt SG
J Immunother Cancer; 2019 Feb; 7(1):37. PubMed ID: 30736857
[TBL] [Abstract][Full Text] [Related]
17. irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial.
Pignon JC; Jegede O; Shukla SA; Braun DA; Horak CE; Wind-Rotolo M; Ishii Y; Catalano PJ; Grosha J; Flaifel A; Novak JS; Mahoney KM; Freeman GJ; Sharpe AH; Hodi FS; Motzer RJ; Choueiri TK; Wu CJ; Atkins MB; McDermott DF; Signoretti S
Clin Cancer Res; 2019 Apr; 25(7):2174-2184. PubMed ID: 30670497
[TBL] [Abstract][Full Text] [Related]
18. Relationships between regulatory T cells and CD8+ effector populations in patients with squamous cell carcinoma of the head and neck.
Chikamatsu K; Sakakura K; Whiteside TL; Furuya N
Head Neck; 2007 Feb; 29(2):120-7. PubMed ID: 17103408
[TBL] [Abstract][Full Text] [Related]
19. Increased PD-1
Jie HB; Srivastava RM; Argiris A; Bauman JE; Kane LP; Ferris RL
Cancer Immunol Res; 2017 May; 5(5):408-416. PubMed ID: 28408386
[TBL] [Abstract][Full Text] [Related]
20. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
